Ractigen Therapeutics Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Series A1

  • Latest Deal Amount
  • $31.4M

  • Investors
  • 9

Ractigen Therapeutics General Information

Description

Developer of RNAa (RNA activation) based therapeutic platform. The company aims to bring therapies designed to selectively restore the expression of therapeutic genes silenced in diseased cells. Its platform utilizes RNA activation technology, enabling clients to specifically target and up-regulate therapeutic genes inside cells of the body. The company's mission is to offer a practical solution to combat disease at the genetic and epigenetic level.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • Bldg.18, Rudong Life & Health Industry Park
  • No. 888 Zhujiang Rd, Rudong County
  • Nantong, Jiangsu 226400
  • China
+86 0513 0000 0000

Ractigen Therapeutics Timeline

2021202220232024
Financing Round

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ractigen Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series A1) 27-Jan-2022 $31.4M 000.00 Completed Pre-Clinical Trials
2. Early Stage VC (Series A) 11-Feb-2021 0000 000.00 Completed Pre-Clinical Trials
1. Seed Round 25-Oct-2016 $7.46M $7.46M Completed Startup
To view Ractigen Therapeutics’s complete valuation and funding history, request access »

Ractigen Therapeutics Patents

Ractigen Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3225998-A1 Oligonucleotide-based delivery vehicle for oligonucleotides agents and methods of use thereof Pending 07-Jul-2021
AU-2022308123-A1 Oligonucleotide-based delivery vehicle for oligonucleotides agents and methods of use thereof Pending 07-Jul-2021
EP-4288542-A1 Multi-valent oligonucleotide agent and methods of use thereof Pending 08-Feb-2021 000000000
EP-4289952-A1 Chemically modified small activating rna Pending 07-Feb-2021 0000000000
EP-4289953-A1 Double-stranded nucleic acid molecule for treating proliferative vitreoretinopathy and use thereof Pending 07-Feb-2021 A61K47/543
To view Ractigen Therapeutics’s complete patent history, request access »

Ractigen Therapeutics Executive Team (2)

Name Title Board Seat Contact Info
Longcheng Li MD Co-Founder, Chief Executive Officer & Chairman
Harri Järveläinen Ph.D Chief Operating Officer
To view Ractigen Therapeutics’s complete executive team members history, request access »

Ractigen Therapeutics Board Members (1)

Name Representing Role Since
Longcheng Li MD Ractigen Therapeutics Co-Founder, Chief Executive Officer & Chairman 000 0000
To view Ractigen Therapeutics’s complete board members history, request access »

Ractigen Therapeutics Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
China-Singapore Suzhou Industrial Park Development Group Corporation Minority 000 0000 000000 0
Eisai Corporation Minority 000 0000 000000 0
HM Capital Venture Capital Minority 000 0000 000000 0
Ling Cheng Ventures Venture Capital Minority 000 0000 000000 0
SDIC Venture Capital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »